Recombinant multi-species RNASEH2A protein for cell curture, in vitro study, in vivo study, benchmark, drug discovery & MOA research and positive control for the diagnosis

Genemedi produces recombinant Human, Cynomolgus/ Rhesus macaque, Rat, Mouse, Feline, Canine, Bovine, Equine RNASEH2A protein for cell curture, in vitro study, in vivo study, benchmark, drug discovery & MOA research and positive control for the diagnosis.
The protein encoded by this gene is a component of the heterotrimeric type II ribonuclease H enzyme (RNAseH2). RNAseH2 is the major source of ribonuclease H activity in mammalian cells and endonucleolytically cleaves ribonucleotides. It is predicted to remove Okazaki fragment RNA primers during lagging strand DNA synthesis and to excise single ribonucleotides from DNA-DNA duplexes. Mutations in this gene cause Aicardi-Goutieres Syndrome (AGS), a an autosomal recessive neurological disorder characterized by progressive microcephaly and psychomotor retardation, intracranial calcifications, elevated levels of interferon-alpha and white blood cells in the cerebrospinal fluid.[provided by RefSeq, Aug 2009]
The Alternative Names of target: RNASEH2A,Ribonuclease H2 subunit A,RNase H2 subunit A,Aicardi-Goutieres syndrome 4 protein (AGS4), RNase H(35), Ribonuclease HI large subunit (RNase HI large subunit), Ribonuclease HI subunit A,AGS4,JUNB,RNHL,RNHIA,RNASEHI

Target products collectionGo to RNASEH2A products collection >>
(antibodies, antigen, VLP, mRNA, ORF viral vector, etc)

pdfMSDSpdfCOApdfDatasheet

Product information

Catalog No. Product Name Species Reactivity
GM-Tg-hg-TA020-Ab-1/ GM-Tg-hg-TA020-Ab-2 Human RNASEH2A protein Human
GM-Tg-rg-TA020-Ab-1/ GM-Tg-rg-TA020-Ab-2 Rat RNASEH2A protein Rat
GM-Tg-mg-TA020-Ab-1/ GM-Tg-mg-TA020-Ab-2 Mouse RNASEH2A protein Mouse
GM-Tg-cynog-TA020-Ab-1/ GM-Tg-cynog-TA020-Ab-2 Cynomolgus/Rhesus macaque RNASEH2A monoclonal antibody Cynomolgus/ Rhesus macaque
GM-Tg-felg-TA020-Ab-1/ GM-Tg-felg-TA020-Ab-2 Feline RNASEH2A protein Feline
GM-Tg-cang-TA020-Ab-1/ GM-Tg-cang-TA020-Ab-2 Canine RNASEH2A protein Canine
GM-Tg-bovg-TA020-Ab-1/ GM-Tg-bovg-TA020-Ab-2 Bovine RNASEH2A protein Bovine
GM-Tg-equg-TA020-Ab-1/ GM-Tg-equg-TA020-Ab-2 Equine RNASEH2A protein Equine

Size： 1mg | 10mg | 100mg



Product Description

Catalog No. GM-Tg-hg-TA020-Ab-1/ GM-Tg-hg-TA020-Ab-2; GM-Tg-rg-TA020-Ab-1/ GM-Tg-rg-TA020-Ab-2;
GM-Tg-mg-TA020-Ab-1/ GM-Tg-mg-TA020-Ab-2; GM-Tg-cynog-TA020-Ab-1/ GM-Tg-cynog-TA020-Ab-2;
GM-Tg-felg-TA020-Ab-1/ GM-Tg-felg-TA020-Ab-2; GM-Tg-cang-TA020-Ab-1/ GM-Tg-cang-TA020-Ab-2;
GM-Tg-bovg-TA020-Ab-1/ GM-Tg-bovg-TA020-Ab-2; GM-Tg-equg-TA020-Ab-1/ GM-Tg-equg-TA020-Ab-2
Products Name RNASEH2A protein
Species Human, Cynomolgus/ Rhesus macaque, rat, mouse, Feline, Canine, Bovine, Equine
Target Name RNASEH2A
Protein Sub-location Introcelluar Protein
Isotypes Recombinant protein
Expression platform Mammalian cell
Bioactivity validation Affintiy&bioactivity validated by ELISA, cell culture validated.
Tag His
Products description Recombinant Human, Cynomolgus/ Rhesus macaque, Rat, Mouse, Feline, Canine, Bovine, Equine RNASEH2A protein was expressed in mammalian cell expression system and is expressed with 6 HIS tag at the C-terminus for cell culture, ELISA or other affinity binding assay or functional assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic).
Purity Purity: ≥95% (SDS-PAGE)
Application In vitro study, in vivo study, benchmark, positive control for the diagnosis. Biological drug disovery including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Formulation & Reconstitution Lyophilized from GM's Protein Stability Buffer2 (PSB2,Confidential Ingredients) or PBS (pH7.4);
For PSB2, reconstituted with 0.9% sodium chloride;
For PBS, reconstituted with ddH2O.
Storage Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles.

Reference






    About Gmab

    GDU
    GDU

    GMab, developed by GeneMedi, constitutes an advanced library of recombinant monoclonal antibodies, each meticulously designed to target specific molecular entities. Leveraging the sophisticated capabilities of GM’s Taurus™ and LIBRA™ platforms, GMab synthesizes antibodies characterized by high binding affinity, exceptional physicochemical stability, and optimal developability profiles.
    Through expression in mammalian cell lines, GMab has been established as a paradigmatic reference antibody. It holds significance in myriad domains of biological drug discovery, encompassing cellular cultivation, innovative assay methodologies, strategic animal model systematization, in-depth pharmacokinetic & pharmacodynamic (PK/PD) modeling, and intricate mechanism of action (MOA) investigations.